Ethiopian Barega Upsets Uganda’s Cheptegei to Win Shock 10,000-Meter Gold

Ethiopia’s Selemon Barega sprinted the last lap to beat world record holder Joshua Cheptegei of Uganda and win a shock Olympic gold medal in the men’s 10,000 meters on Friday.
The 21-year-old Barega powered down the home straight to cross the line in 27 minutes 43.22 seconds, ahead of world champion Cheptegei in 27:43.63.
Jacob Kiplimo, the youngest-ever Ugandan Olympian when he ran the 5,000 heats in Rio as a 15-year-old, posted a time of 27:43.88 to secure bronze in the first athletics medal event of the Games.
Barega, the 2019 5,000-meter world championship silver medalist who set the second-fastest 10,000-meter time of the year in June, was applauded by the Ethiopian delegation as he smiled broadly on a victory lap with his country’s flag draped around his shoulders.
Cheptegei said he was experiencing mixed emotions.
“I have two feelings. One is that I’m very happy to have won an Olympic silver medal today,” he told reporters. “But the other side of me is really not satisfied with the result because I came here expecting to win a gold.”
Cheptegei also admitted that 2021 had been tough for him.
“This year was really a very difficult year for me in terms of racing,” he said. “It’s the year that I have lost all the focus, all the belief. There was a lot of pressure and I was feeling it in every moment.”
Uganda’s Stephen Kissa acted as the early pacemaker before dropping out a little over halfway through the race.
“We had a plan for me to go ahead to make it a fast race,” Kissa told reporters. “I thought they were going to follow me but when I looked round they were not there.”
Cheptegei led briefly before dropping back into the pack and Barega seized his chance, moving among the leaders in the last third of the race before hitting the front with a surge on the last lap to secure his surprise victory.

Source: Voice of America

Explosion Kills Three Soccer Players in Somalia’s Kismayo

At least three soccer players were killed, and six others injured in an explosion Friday in the southern Somali port town of Kismayo, a police officer confirmed.
Mohamed Guled Hassan, deputy commander of Jubaland regional police forces, told VOA Somali that the blast was caused by a bomb planted on a bus carrying a local soccer team.
The bomb was “apparently planted on the bus carrying young players on their way to attend a soccer tournament, which was opening in the town. Three of them were killed and six others were hospitalized for injuries,” said Hassan.
No group has so far claimed responsibility for the attack, but the police commander has placed the blame on Somali militant group al-Shabab.
“This heinous attack against young innocent players is another evidence of the terrorists’ enmity against the lives of Somali youth,” read a short statement on Twitter from Somali President Mohamed Abdullahi Farmajo.
The motive for the attack was unknown. The attack came a day after the Jubaland State assembly met in Kismayo and elected four members of the country’s upper house of parliament. Al-Shabab has threatened to attack anyone involved in the election process.
Elections
The vote Thursday was a crucial a first step toward a new parliament and president in Somalia. The voting was held in a highly secured venue in Kismayo, which was once a stronghold for the al-Shabab terror group.
“We have held the election of four members of our eight seats in the Somalia Upper House today. It was a very successful step taken forward,” said the chairman of the Jubaland State electoral commission, Siyad Mohamed Mursal.
Somalia does not have one person, one vote elections. The country’s powerful clans will choose members of the lower house of parliament, while state assemblies will elect members of the upper house.
No dates have been set for the election of other lawmakers. The elections have been repeatedly postponed due to disagreements on the process between the government and opposition.
Speaking to VOA Somali, the chairman of Somali Federal Electoral Commission, Mohamed Hassan Irro, said Thursday’s election in Kismayo was a milestone.
“It was the beginning of a full success for our long-delayed elections. It was held under secure smooth and a democratic process. We hope that the other states in the country will do the same because process is on the right track despite the setbacks.” said Irro.

Source: Voice of America

Mozambique’s President Welcomes African Troops Sent to Fight Insurgents

Mozambique’s defense minister says South African troops are expected this week to join operations meant to counter insurgents in northern Cabo Delgado province.
Defense Minister Jaime Neto says terrorists are being cornered as a result of intense operations by Mozambican and Rwanda forces in Cabo Delgado.
Briefing the media in Maputo on Friday, the defense minister said it was difficult to count the number of insurgents killed in the operations.
He was referring to an announcement made by Rwandan authorities in Kigali about the killing of 14 terrorists in Cabo Delgado during an operation this week.
Rwandan soldiers, who arrived in Cabo Delgado about a week ago, are fighting alongside Mozambican troops under the framework of a bilateral agreement.
In addition to Rwanda, Mozambique will have support from the Southern African Development Community (SADC), following the approval by regional leaders of a “joint standby force” during a summit in Maputo last month.
Neto said Rwanda and Mozambique are operating together but SADC will start. The contingents will arrive. He said I think the South African contingent will start very soon, within this week, which is significant but also a contingent from Botswana is coming. He said an Angolan contingent will also arrive and part of it is already on the ground.
The number of soldiers the regional bloc will send to Mozambique is not publicly known, but experts from the SADC, who were in Cabo Delgado, proposed that the mission should have around 3,000 soldiers.
Armed groups have terrorized Cabo Delgado province since 2017, with some attacks being claimed by the Islamic State militant group.
Humanitarian organizations estimate that more than 3,100 people have been killed and up to a million others displaced.

Source: Voice of America

Malawi Ready to Store, Distribute Incoming COVID-19 Vaccine: Official

Queen Dube is chief of health services in Malawi’s Ministry of Health. She said there will be no repeat of that incident, because a government campaign has now convinced Malawians the vaccines are safe and protective.

She notes that a recent consignment of 192,000 AstraZeneca vaccines, which the country received last Saturday were gone within days.

Even if some of the donated vaccines are due to expire soon, they will be distributed within sufficient time, she said.

“It’s this scenario where you have one week of shelf-life left that puts you in very difficult circumstances,” Dube said. “But, you know, we have created demand. Remember on 27th [July] we vaccinated 75,000 people and so even if we had all those doses that were to expire in two weeks, say for example 100,000 doses, we should be able to quickly use them within two, three days.”

Dr. Alinafe Kasiya is a public health expert with Village Reach, an international health charity that is supporting vaccine delivery in African countries.

He said countries need to think about their storage and distribution systems.

“That means a number of things; Do we have enough capacity to be able to store the vaccines that are coming?” Kasiya said. “I mean some of the vaccines might have different cold chain requirements. But also do we have a logistic system in place to be able to move these vaccines around? Do we have enough people trained? Are we opening up enough sites? Are we looking at doing more to create demand?”

Kasiya, the country director for Village Reach in Malawi, applauds Malawi’s government for creating demand for the vaccine.

Queen Dube says even though the Pfizer vaccine needs ultra-cold storage, no doses will be wasted.

“There are two things with Pfizer,” Dube said. “We now have evidence that if you take it out of an ultra-cold system you can store it at temperatures between two to eight degrees. These are normal temperatures that we store our vaccines in; and you can use it for 31 days.”

So far, Malawi has recorded about 51,000 cases of COVID-19 and nearly 1,600 deaths. Only a tiny fraction of the country’s 18 million people have been inoculated, though that number will quickly rise if more people cooperate with the government’s vaccination campaign.

 

 

Source: Voice of America

Millions in 23 Hunger Hot Spots Face Famine, Death, UN Agencies Say

The United Nations warns global hunger is increasing and urgent action is needed to stave off famine and death over coming months in nearly two dozen unstable, violence-prone countries.
A report by the U.N. Food and Agriculture Organization and the World Food Program said more than a half-million people are experiencing catastrophic levels of acute food insecurity and 41 million are at risk of famine.
The report from the WFP and FAO focuses on the particularly serious situation in 23 so-called hunger hot spots. Most of those countries are in sub-Saharan Africa, with others in Central America, Asia and the Middle East.
Patrick Jacqueson, FAO officer in charge of the Geneva office, said acute hunger is set to increase in those countries over the next four months without urgent, scaled-up humanitarian assistance.
“Conflict continues to be the primary driver for the largest share of people facing acute food insecurity,” Jacqueson said. “Closely associated with conflict are humanitarian access constraints, which remain significant, compounding food insecurity. Weather extremes and climate variability are likely to affect several parts of the world during the outlook period.”
The report said dry conditions are likely to affect Haiti, Nigeria’s Middle Belt and the “Dry Corridor” in Guatemala, while above-average rainfall and flooding are forecast in South Sudan, central and eastern Sahel, and Gulf of Guinea countries.
400,000 face starvation in Tigray
The report highlighted the perilous situation in Ethiopia and Madagascar, the world’s newest highest-alert hunger hot spots.
Annalisa Conte, WFP Geneva Office director, said the aggravation of conflict in recent months is having a catastrophic impact on the food security of the Tigrayan population in Ethiopia. She warned that more than 400,000 people would face starvation if they did not receive sufficient humanitarian aid.
“If we move to Madagascar, Madagascar is experiencing the worst drought in 40 years,” Conte said. “On top of that, economic decline largely caused by COVID. As a result, 1.3 million people are currently facing the acute food insecurity.”
The FAO and WFP said fighting, blockades that cut off lifesaving aid to families on the verge of famine, and a lack of funding were hampering efforts to provide emergency food aid to millions of desperate people.
The agencies said families who rely on humanitarian aid to survive were hanging by a thread. They noted that most of those on the verge of famine in the 23 hot spots were farmers and must receive help to resume food production. That, they said, will allow them to feed themselves and become self-sufficient.

Source: Voice of America

International Aid Cuts to Affect Millions Across Africa

The COVID-19 pandemic has led to cuts in foreign aid from donor nations such as Britain — which cut its aid budget by $5.5 billion — Australia, Japan and Saudi Arabia. The funding loss is being felt in Burkina Faso, where it could shut down a group that helps thousands of survivors of gender-based violence and rape.
The largest international nonprofits say the shock waves of the cuts will be felt by people across Africa in all kinds of situations and will result in deaths.
“For countries like the [United Kingdom] and others to be cutting their aid budgets in a global pandemic is extremely shortsighted, and we know it will put the fight back against poverty by many decades,” said Sam Nadel, Oxfam government relations chief. “So, the U.N. secretary general, for example, has called these cuts a death sentence, and it really is that stark for many people.”
Marie Stopes, a group offering family planning to countries in crisis like Burkina Faso, is primarily supported by British aid money.
The cuts will impact large numbers of women, according to the head of Marie Stopes-Burkina Faso, Dr. Toumbi Sissoko. The group has been able to assist more than 500,000 people over two years, she said.
“Alice,” whose name has been changed to protect her identity, received help from Marie Stopes after she fled her village in northern Burkina Faso, when gunmen attacked. She trekked through the bush for three days, seeking refuge, but then was seized by a group of terrorists.
She says they told her to put her daughter down, before one of them hit her with the back of his gun, knocking her to the ground. Six of them raped her, then discussed whether they should kill her, but, she says, they concluded it was useless to kill a woman. They got on their motorbikes and left.
When she reached the relative safety of Kaya the next day, she was directed to Marie Stopes-Burkina Faso.
Alice says a woman from Marie Stopes immediately gave her morning-after pills and advice. She was still traumatized and could neither eat nor breastfeed her daughter. She says that the woman at Marie Stopes encouraged her to eat and told her that her life was still worth living.
Flora Guibere, who works for Marie Stopes, fears that with the foreign aid cuts, beneficiaries will be left on their own, and many of her organization’s workers will be out of a job.
For women like Alice who fall victim to gang rape, it will mean they may no longer receive emergency birth control or support.

Source: Voice of America

Takeda and Frazier Healthcare Partners Announce Collaboration to Launch HilleVax, Inc. to Develop Clinical Stage Norovirus Vaccine Candidate

Takeda Will Focus its Efforts on Dengue, Zika and Pandemic Vaccines

Dubai, United Arab Emirates, July 30, 2021 (GLOBE NEWSWIRE) — Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (Takeda) and Frazier Healthcare Partners (Frazier) today announced a collaboration to launch HilleVax, Inc. (HilleVax), a biopharmaceutical company to develop and commercialize Takeda’s norovirus vaccine candidate. Takeda has granted a license to HilleVax for the exclusive development and commercialization rights to its norovirus vaccine candidate, HIL-214 (formerly TAK-214), worldwide outside of Japan. Takeda will retain commercialization rights in Japan and HilleVax will integrate certain Japan development activities into its global development. Takeda remains committed to vaccines and this collaboration allows Takeda to focus primarily on dengue, COVID-19, pandemic influenza and Zika.

HIL-214, which is a virus-like particle (VLP) based vaccine candidate, completed a randomized, placebo-controlled Phase 2b field efficacy study in 4,712 adult subjects in which HIL-214 was well-tolerated and demonstrated clinical proof of concept in preventing moderate-to-severe cases of acute gastroenteritis from norovirus infection.1 To date, the candidate has been studied in nine human clinical trials with safety data from over 4,500 subjects and immunogenicity data from over 2,000 subjects.

Ursula Belinda Myles, General Manager of Takeda’s Access Market Cluster (covering much of Africa) commented: “Africa’s underlying burden of endemic diseases is one of the largest in the world, and infectious diseases play a larger portion of these diseases across the continent. Like many other nations, COVID-19 has emphasized Africa’s greatest challenges around healthcare and highlighted the need for continued greater investment in healthcare systems. These investments are critical to secure economic development as Africa implements flagship projects around the 2030 Africa Health Strategy.”

Ursula added: “The announcement of our partnership with Frazier Healthcare Partners will allow Takeda to focus efforts and resources on vaccines for diseases prevalent across Africa and provide support in alleviating the growing burden that infectious diseases have on public health systems.”

Norovirus is a common intestinal infection marked by diarrhea, vomiting, abdominal cramps, nausea and sometimes fever that may lead to clinically significant dehydration.2 Norovirus is recognized as the leading cause of acute gastroenteritis across the age spectrum.3 It is estimated that norovirus causes nearly 700 million cases of illness and more than 200,000 deaths worldwide per year with significant additional economic and social burden.3 No vaccines are currently approved for norovirus infection, and HIL-214 continues to be the most advanced norovirus vaccine candidate in human clinical trials.

“Takeda and Frazier have a history of successfully partnering together, and we are confident in HilleVax’s capabilities to progress HIL-214, the most advanced norovirus vaccine candidate in development with the potential to address the huge global burden of norovirus-associated acute gastroenteritis,” said Rajeev Venkayya, M.D., President of the Global Vaccine Business Unit, Takeda. “This will allow Takeda to focus its efforts and resources on our dengue vaccine, which we have begun filing for licensure around the world, our pandemic programs, and our partnership with the US Government to develop a Zika vaccine

 Takeda’s Commitment to Vaccines

Vaccines prevent 2 to 3 million deaths each year and have transformed global public health. For more than 70 years, Takeda has supplied vaccines to protect the health of people in Japan. Today, Takeda’s global vaccine business is applying innovation to tackle some of the world’s most challenging infectious diseases, such as dengue, COVID-19, pandemic influenza and Zika. Takeda’s team brings an outstanding track record and a wealth of knowledge in vaccine development and manufacturing to advance a pipeline of vaccines to address some of the world’s most pressing public health needs. For more information, visit www.TakedaVaccines.com.

About Takeda Pharmaceutical Company Limited
Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) is a global, values-based, R&D-driven biopharmaceutical leader headquartered in Japan, committed to discover and deliver life-transforming treatments, guided by our commitment to patients, our people and the planet. Takeda focuses its R&D efforts on four therapeutic areas: Oncology, Rare Genetic and Hematology, Neuroscience and Gastroenterology (GI). We also make targeted R&D investments in Plasma-Derived Therapies and Vaccines. We are focusing on developing highly innovative medicines that contribute to making a difference in people’s lives by advancing the frontier of new treatment options and leveraging our enhanced collaborative R&D engine and capabilities to create a robust, modality-diverse pipeline. Our employees are committed to improving quality of life for patients and to working with our partners in health care in approximately 80 countries and regions. For more information, visit https://www.takeda.com.

About Frazier Healthcare Partners

Founded in 1991, Frazier Healthcare Partners is a leading provider of growth and venture capital to healthcare companies. With nearly $4.8 billion total capital raised, Frazier has invested in over 200 companies, with investment types ranging from company creation and venture capital to buyouts of profitable lower-middle market companies. The firm’s Growth Buyout team invests in healthcare and pharmaceutical services, medical products and related sectors. The Life Sciences team invests in therapeutics and related areas that are addressing unmet medical needs through innovation. Frazier has offices in Seattle, WA and Menlo Park, CA, and invests broadly across the US, Canada, and Europe. For more information about Frazier Healthcare Partners, visit the company’s website at http://www.frazierhealthcare.com.

About HilleVax

HilleVax is a biopharmaceutical company focused on the development and commercialization of novel vaccine candidates.  Its initial program, HIL-214, is a virus-like particle (VLP) based vaccine candidate in development for the prevention of moderate-to-severe acute gastroenteritis caused by norovirus infection. For more information about HilleVax, visit the company’s website at http://www.HilleVax.com.

Takeda Pharmaceutical Company Limited Forward-Looking Statements

This press release and any materials distributed in connection with this press release may contain forward-looking statements, beliefs or opinions regarding Takeda’s future business, future position and results of operations, including estimates, forecasts, targets and plans for Takeda. Without limitation, forward-looking statements often include words such as “targets”, “plans”, “believes”, “hopes”, “continues”, “expects”, “aims”, “intends”, “ensures”, “will”, “may”, “should”, “would”, “could” “anticipates”, “estimates”, “projects” or similar expressions or the negative thereof. These forward-looking statements are based on assumptions about many important factors, including the following, which could cause actual results to differ materially from those expressed or implied by the forward-looking statements: the economic circumstances surrounding Takeda’s global business, including general economic conditions in Japan and the United States; competitive pressures and developments; changes to applicable laws and regulations; the success of or failure of product development programs; decisions of regulatory authorities and the timing thereof; fluctuations in interest and currency exchange rates; claims or concerns regarding the safety or efficacy of marketed products or product candidates; the impact of health crises, like the novel coronavirus pandemic, on Takeda and its customers and suppliers, including foreign governments in countries in which Takeda operates, or on other facets of its business; the timing and impact of post-merger integration efforts with acquired companies; the ability to divest assets that are not core to Takeda’s operations and the timing of any such divestment(s); and other factors identified in Takeda’s most recent Annual Report on Form 20-F and Takeda’s other reports filed with the U.S. Securities and Exchange Commission, available on Takeda’s website at: https://www.takeda.com/investors/reports/sec-filings/ or at www.sec.gov. Takeda does not undertake to update any of the forward-looking statements contained in this press release or any other forward-looking statements it may make, except as required by law or stock exchange rule. Past performance is not an indicator of future results and the results or statements of Takeda in this press release may not be indicative of, and are not an estimate, forecast, guarantee or projection of Takeda’s future results.

 CONTACTS:

Takeda Media Contacts:
Japanese Media

Ryoko Matsumoto

ryoko.matsumoto@takeda.com

+81 (0) 3-3278-3414

edia Outside Japan

Amy Atwood

amy.atwood@takeda.com

+1-774-571-3316

For HilleVax, Inc.: For Frazier Healthcare Partners:
David Socks

info@hillevax.com

+1-650-325-5156

Liz Park

liz.park@frazierhealthcare.com

+1-650-319-1831

References

1 Sherwood J, et al. Vaccine 2020; 38(41):6442-6449

2 https://ww.cdc.gov/norovirus/index.html [accessed 2021 April 27].

3 Hall AJ, et al. Expert Rev Vaccines 2016;15(8):949-951

Mohammed Al Nasseri
Takeda Pharmaceuticals
+971507694646
Mohammed.alnasseri@fleishman.com